Evidence map›Paper›PMID 36398545›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2022

[Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity].

Qing-Fei Hao, Jing Chen, Peng Ruan, Gao-Pan Li, Jing Zhang, Hao-Ming Chen, Hong-Xiang Guo, Xiao-Juan Sun, Xiu-Yong Cheng

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Qing-Fei HaoDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Jing ChenDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Peng RuanDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Gao-Pan LiDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Jing ZhangDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Hao-Ming ChenDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Hong-Xiang GuoDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Xiao-Juan SunDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Xiu-Yong ChengDepartment of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence.

methodsA retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment.

resultsAfter one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (

conclusionsIntravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.

Indexed as

Hypertension, Pregnancy-InducedRetinopathy of PrematurityAngiogenesis InhibitorsEndothelial Growth FactorsFemaleHemorrhageHumansInfantInfant, NewbornOxygenPregnancyRetrospective StudiesRisk FactorsVascular Endothelial Growth Factor AAngiogenesis InhibitorsEndothelial Growth FactorsOxygenVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorPreterm infantRecurrenceRetinopathy of prematurity

Identifiers

PMID36398545
PMCPMC9678068
OpenAlexW4309509488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.